Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$472.64 USD
-8.10 (-1.68%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $471.66 -0.98 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Thermo Fisher Scientific Inc. has a PEG ratio of 2.64 compared to the Medical - Instruments industry's PEG ratio of 2.51.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TMO 472.64 -8.10(-1.68%)
Will TMO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMO
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
Beat the Market the Zacks Way: CommScope, Micron, Oracle in Focus
TMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hologic's Panther Fusion Signals More Molecular Diagnostics Upside
Why Is Idexx (IDXX) Down 0.4% Since Last Earnings Report?
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus
Other News for TMO
Is TMO signaling a buying opportunity? Crossed Above 200 Day Moving Average shows up after climbing 1.32%
TMO forms 200 Day Moving Average Resistance on September 15
Thermo Fisher (TMO) Enhances U.S. Distribution for Harvard Bioscience Products
Harvard Bioscience expands distribution agreement with Fisher Scientific
Harvard Bioscience expands distribution agreement with Fisher Scientific